GSI-I has a better effect in inhibiting hepatocellular carcinoma cell growth than GSI-IX, GSI-X, or GSI-XXI

Anti-Cancer Drugs

Volumn 23, Issue 7, 2012, Pages 683-690

  Shen, Yuqing ^a   Lv, Dan ^a   Wang, Jie ^a   Yin, Ying ^a   Miao, Fengqin ^a   Dou, Fei ^b   Zhang, Jianqiong ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b BEIJING NORMAL UNIVERSITY   (China)

Author keywords

c secretase inhibitor; hepatocellular carcinoma; Notch signaling; proliferationsignaling

Indexed keywords

GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR 1; GAMMA SECRETASE INHIBITOR 9; JAGGED1; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZODIAZEPINONES; CALCIUM-BINDING PROTEINS; CARBAMATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIPEPTIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HEP G2 CELLS; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MEMBRANE PROTEINS; OLIGOPEPTIDES; RECEPTORS, NOTCH;

EID: 84863590292     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283549a22     Document Type: Article

References (29)

1. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg 2011; 253:453-469.
2. Kim HY, Park JW. Molecularly targeted therapies for hepatocellular carcinoma: Sorafenib as a stepping stone. Dig Dis 2011; 29:303-309.
3. Mishra L. The 21st century hepatologist and a systems biology based approach to liver diseases. Hepatology 2008; 48:1731-1733.
4. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol 2011; 224:448-460.
5. Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-Cell acute lymphoblastic leukemia cells. Cancer Res 2009; 69:3060-3068.
6. Hu YY, Zheng MH, Cheng G, Li L, Liang L, Gao F, et al. Notch signaling contributes to the maintenance of both normal neural stem cells and patientderived glioma stem cells. BMC Cancer 2011; 11:82.
7. Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E, Coombes RC. Inhibition of gamma-Secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 2009; 100:1879-1888.
8. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. Preclinical profile of a potent gamma-Secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009; 69:7672-7680.
9. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, et al. Inhibition of gamma-Secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009; 136:1741-1749, e1746.
10. Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, et al. Gamma-Secretase inhibitors target tumor-Initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 2012; 31:93-103.
11. Imbimbo BP, Giardina GA. Gamma-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: Disappointments and hopes. Curr Top Med Chem 2011; 11:1555-1570.
12. Lin J, Zhang XM, Yang JC, Ye YB, Luo SQ. Gamma-Secretase inhibitor-i enhances radiosensitivity of glioblastoma cell lines by depleting CD133 + tumor cells. Arch Med Res 2011; 41:519-529.
13. Wang M, Wu L, Wang L, Xin X. Down-Regulation of Notch1 by gammasecretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun 2010; 393:144-149.
14. Yao J, Duan L, Fan M, Wu X. Gamma-Secretase inhibitors exert antitumor activity via down-Regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells. Oral Dis 2007; 13:555-563. (Pubitemid 47609890)
15. Ferrari-TONINELLI G, Bonini SA, Uberti D, Buizza L, Bettinsoli P, Poliani PL, et al. Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol 2010; 12:1231-1243.
16. Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63:8323-8329. (Pubitemid 37549485)
17. Gao J, Song Z, Chen Y, Xia L,Wang J, Fan R, et al. Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig Liver Dis 2008; 40:114-121.
18. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int 2007; 27:997-1007. (Pubitemid 47261955)
19. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, et al. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol 2009; 50:969-979.
20. Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, et al. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res 2010; 316: 149-157.
21. Suwanjunee S, Wongchana W, Palaga T. Inhibition of gamma-Secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling. Anticancer Drugs 2008; 19:477-486. (Pubitemid 351556399)
22. Nijjar SS, Wallace L, Crosby HA, Hubscher SG, Strain AJ. Altered Notch ligand expression in human liver disease: Further evidence for a role of the Notch signaling pathway in hepatic neovascularization and biliary ductular defects. Am J Pathol 2002; 160:1695-1703. (Pubitemid 34525649)
23. Ferrando A. NOTCH mutations as prognostic markers in T-all. Leukemia 2010; 24:2003-2004.
24. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-Cell acute lymphoblastic leukemia. Leukemia 2009; 23:1374-1377.
25. Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, et al. Combined inhibition of Notch signaling and Bcl-2/Bcl-xl results in synergistic antimyeloma effect. Mol Cancer Ther 2010; 9:3200-3209.
26. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 2011; 17:103-112.
27. Wang F, Zhou H, Xia X, Sun Q,Wang Y, Cheng B. Activated Notch signaling is required for hepatitis B virus X protein to promote proliferation and survival of human hepatic cells. Cancer Lett 2010; 298:64-73.
28. Meng X, Matlawska-WASOWSKA K, Girodon F, Mazel T,Willman CL, Atlas S, et al. GSI-i (Z-Llnle-cho) inhibits gamma-Secretase and the proteosome to trigger cell death in precursor-b acute lymphoblastic leukemia. Leukemia 2011; 25:1135-1146.
29. Han J, Ma I, Hendzel MJ, Allalunis-TURNER J. The cytotoxicity of gammasecretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-Secretase inhibition. Breast Cancer Res 2009; 11:R57.